Casi pharmaceuticals, inc. announces an exclusive distribution agreement with pharmathen global bv

Casi pharmaceuticals, inc. announced an exclusive distribution agreement with pharmathen global bv for the development and distribution of octreotide long acting injectable (lai) microsphere in china. octreotide lai formulations are considered a standard of care for the treatment of acromegaly and for the control of symptoms associated with certain neuroendocrine tumors. pharmathen has received regulatory approvals in various european countries. casi will be responsible for the development, import drug registration and product approval in china and has a long-term exclusive distribution right for the china market after product launch.
CASI Ratings Summary
CASI Quant Ranking